Suppliers and packagers for eliquis

eliquis

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155	NDA	E.R. Squibb & Sons, L.L.C.	0003-0893-21	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0893-21)	2012-12-28
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155	NDA	E.R. Squibb & Sons, L.L.C.	0003-0893-31	10 BLISTER PACK in 1 CARTON (0003-0893-31) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2012-12-28
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155	NDA	E.R. Squibb & Sons, L.L.C.	0003-0893-91	1 BLISTER PACK in 1 CARTON (0003-0893-91) / 14 TABLET, FILM COATED in 1 BLISTER PACK	2012-12-28
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155	NDA	E.R. Squibb & Sons, L.L.C.	0003-0894-21	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0894-21)	2012-12-28

Last updated: September 17, 2025

ppliers for the Pharmaceutical Drug: ELIQUIS

Introduction
ELIQUIS (apixaban) is a widely prescribed oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. As a direct Factor Xa inhibitor, ELIQUIS plays a pivotal role in thrombosis prevention and treatment, including atrial fibrillation-related stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). Given its global demand, understanding its suppliers — encompassing active pharmaceutical ingredient (API) producers, finished drug manufacturers, and distribution channels — is vital for stakeholders assessing supply chain stability, market strategy, and regulatory compliance.

Manufacturers of ELIQUIS API
The core component of ELIQUIS is apixaban, the active pharmaceutical ingredient (API). Several specialized chemical manufacturers produce apixaban API for Bristol-Myers Squibb, Pfizer, and authorized generic producers.

• Fujifilm Toyama Chemical Co., Ltd.
  As one of the original API suppliers, Fujifilm has been involved in apixaban synthesis, leveraging its extensive expertise in fine chemical production. The company's manufacturing facilities are certified under international standards, ensuring consistent API quality for branded and generic formulations. [1]

• Covalent Laboratories Inc.
  This US-based firm specializes in synthesizing high-purity active pharmaceutical ingredients, including apixaban. Covalent's integrated manufacturing process emphasizes batch consistency, critical for anticoagulant drugs where dosage precision impacts safety and efficacy. [2]

• Haohong Pharmaceutical Co., Ltd.
  A Chinese API manufacturer, Haohong has entered the apixaban supply chain, aiming to meet increasing global demand. Its facilities comply with GMP standards, supporting exports to North America, Europe, and Asia. Lower production costs and capacity expansion are part of its strategic growth. [3]

• Wuxi AppTec Co., Ltd.
  A prominent contract development and manufacturing organization (CDMO), Wuxi AppTec offers apixaban API synthesis services. Its global network and advanced manufacturing capabilities make it a key player in API supply for generic drug companies. [4]

Finished Drug Manufacturers and Packagers
While Bristol-Myers Squibb and Pfizer are the primary developers and marketers of ELIQUIS, other companies produce generic versions or distribute the drug globally through licensing agreements.

• Bristol-Myers Squibb and Pfizer
  As originators, these companies control the patent rights and manufacture ELIQUIS at their controlled facilities, ensuring strict Quality Control (QC) and regulatory standards. Their supply chains extend across North America, Europe, and Asia, leveraging regional manufacturing hubs.

• Generic Manufacturers
  Following patent expiry in select jurisdictions, multiple generic pharmaceutical companies began producing apixaban-based drugs under licensing agreements or through certification pathways such as ANDA (Abbreviated New Drug Application) in the US or equivalent processes globally. Prominent generic manufacturers include:

  • Teva Pharmaceuticals
    As a major global generic producer, Teva has received approval for apixaban formulations, sourcing API from multiple approved suppliers to ensure cost-effective production. Their extensive distribution network ensures availability in multiple markets. [5]

  • Mylan (now part of Viatris)
    Mylan developed its version of apixaban post-patent expiry, integrating API from various international suppliers, thus diversifying risk and ensuring supply resilience.

  • Zhejiang Huahai Pharmaceutical Co., Ltd.
    This Chinese API manufacturer is also associated with producing generic apixaban formulations for local and export markets, subject to regulatory approval processes.

Distribution and Logistics Channels
ELIQUIS’s supply chain extends beyond API and finished drug manufacturing, encompassing warehousing, distribution, and pharmacy dispensing.

• Global Distribution Networks
  Major pharmaceutical distributors, such as McKesson, Cardinal Health, and Alliance Healthcare, manage ELIQUIS distribution within North America and Europe, ensuring compliance with local regulations and temperature controls vital for anticoagulants.

• Regional Importers and Pharmacies
  In emerging markets, authorized generic producers and regional importers facilitate access, often sourcing API from multiple suppliers to mitigate supply risks and optimize costs.

Regulatory Considerations
Suppliers must adhere to strict regulatory standards, including GMP (Good Manufacturing Practice), ISO certifications, and regional pharmaceutical regulations. The complexity of ELIQUIS’s supply chain underscores the importance of transparency and validation in API sourcing and manufacturing.

Market Risks and Supply Chain Vulnerabilities
Global geopolitics, trade restrictions, and manufacturing disruptions pose risks to ELIQUIS supply continuity. Recent issues with certain Chinese API manufacturers (e.g., Zhejiang Huahai) have highlighted vulnerabilities, prompting companies to diversify sourcing and increase inventory buffers. Supply chain resilience remains a strategic priority for Bristol-Myers Squibb, Pfizer, and generic producers alike.

Emerging Trends and Future Outlook

• API Manufacturing Consolidation
  Increasing consolidation among API suppliers aims to ensure quality, scalability, and regulatory compliance. The market is seeing more CDMOs entering the apixaban supply chain to meet heightened demand and reduce dependence on limited suppliers.

• Bioequivalence and Biosimilar Development
  Research into biosimilar versions of apixaban may influence future supplier dynamics, prompting existing manufacturers to develop more cost-effective or innovative alternatives.

• Sustainability and Ethical Sourcing
  Environmental and ethical standards are gaining prominence, with suppliers adopting greener synthesis processes and transparent supply chains to meet regulatory and societal expectations.

Conclusion
The supplier network for ELIQUIS is characterized by a blend of originators’ controlled manufacturing, diverse API producers across Asia and North America, and a global distribution infrastructure. The resilience of this supply chain hinges on strategic diversification, regulatory compliance, and proactive risk management, ensuring sustained availability of this critical anticoagulant worldwide.

---

Key Takeaways

• Multiple API suppliers, including Fujifilm Toyama, Covalent Labs, Haohong Pharmaceutical, and Wuxi AppTec, underpin ELIQUIS’s production, creating supply diversification.
• Originator companies Bristol-Myers Squibb and Pfizer maintain tight control over manufacturing, with licensed generics emerging post-patent expiry.
• Global distributors and regional importers facilitate ELIQUIS access, emphasizing supply chain resilience and regulatory compliance.
• Market vulnerabilities persist due to geopolitical risks and concentration in certain regions, prompting ongoing diversification and strategic planning.
• Future trends focus on sustainable sourcing, quality enhancement, and biosimilar innovation to maintain market competitiveness.

---

FAQs

1. Who are the primary API suppliers for ELIQUIS (apixaban)?
Major API producers include Fujifilm Toyama, Covalent Laboratories, Haohong Pharmaceutical, and Wuxi AppTec. These companies manufacture apixaban adhering to strict GMP standards to supply both brand-name and generic markets.

2. Are there regional differences in ELIQUIS suppliers?
Yes. North American formulations primarily source API from North American and Western companies like Covalent Labs, while Asian markets often rely on Chinese manufacturers such as Haohong Pharmaceutical and Zhejiang Huahai.

3. How does patent expiry affect ELIQUIS’s supply chain?
Patent expiration has enabled generic manufacturers to produce apixaban, diversifying supply sources and reducing dependence on original developers, thus expanding global access and influencing pricing.

4. What challenges threaten ELIQUIS’s supply chain stability?
Disruptions from geopolitical issues, manufacturing quality concerns (notably in Chinese API plants), regulatory delays, and global supply constraints pose ongoing risks, emphasizing the need for diversification and contingency planning.

5. What future developments could impact suppliers of ELIQUIS?
Advancements in biosimilar and alternative anticoagulant drugs, increased focus on sustainable manufacturing, and changes in regulatory environments will shape supplier strategies and market dynamics in the coming years.

---

References
[1] Fujifilm Toyama Chemical Co., Ltd. Official Website.
[2] Covalent Laboratories Inc. Product Catalog.
[3] Haohong Pharmaceutical Co., Ltd. Company Profile.
[4] Wuxi AppTec. Manufacturing Capabilities.
[5] FDA ANDA Approvals and Patent Data.